A single center, randomized, double blind, 3-treatment, 3-period, single-dose, cross over, comparative Phase-1 study to evaluate pharmacokinetics, safety, tolerability, and pharmacodynamics (PK/PD) of Stelis Teriparatide [rh-PTH (1-34)] with Forsteo and Forteo (teriparatide, Eli Lilly) in healthy volunteers following subcutaneous single dose administration of 20 g Teriparatide
Phase of Trial: Phase I
Latest Information Update: 03 Apr 2018
At a glance
- Drugs Teriparatide (Primary)
- Indications Osteoporosis
- Focus Pharmacokinetics
- Sponsors Quintiles; Stelis Biopharma
- 29 Mar 2018 Planned End Date changed from 30 Apr 2018 to 29 Jun 2018.
- 29 Mar 2018 Status changed from not yet recruiting to recruiting.
- 16 Jan 2018 New trial record